Print Preview

MLH1 promoter methylation analysis, tumor-Pathology add-on

Test info

Test name:

MLH1 promoter methylation analysis, tumor

Test number:

Pathology add-on

Alternate names:

Hypermethylation
MLH1HM
MLH1 hypermethylation
Promoter hypermethylation

Useful for:

MLH1 promoter methylation analysis is useful to distinguish sporadic from inherited colorectal and endometrial cancers in tumors that are MLH1-deficient by IHC staining and/or have high levels of microsatellite instability (MSI-H). The majority of MSI in sporadic cases of these tumors is caused by MLH1 promoter hypermethylation, while hypermethylation is rare in inherited cases.

Specimen

Specimen type:

Solid tumor tissue

Processing instructions:

Submit a formalin-fixed, paraffin-embedded (FFPE) tissue block (preferred)

Transport container:

FFPE tissue block

Alternate transport container:

One (1) H&E slide plus five to 10 (5-10) unstained slides cut at 5 or more microns.
- Use positively-charged slides and 10% NBF fixative
- Do not use zinc fixatives

Transport and stability:

Ambient

Performance

Performing lab:

Neogenomics: R

TAT:

10 days

Method:

Polymerase Chain Reaction (PCR) Analysis

Clinical and Interpretive info

Reference ranges:

An interpretive report will be provided.

Clinical information:

MLH1 promoter methylation analysis results should be considered with other clinical risk factors in determination of likelihood of HNPCC/Lynch Syndrome.

Billing

Preauthorization:

This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.

CPT codes:

81288

Subject to medical necessity (Y/N):

Yes

LCD/NCD:

Medical necessity

Hospital EAP/charge code:

17028037

Clinic EAP/charge code:

308128800

Tracking

Date created:

06/15/2018

Revised date:

06/23/2023

Review date:

12/28/2023